Literature DB >> 25213365

Update on the use of biologics in vasculitides.

Sahana Vishwanath, Manisha Relan, Long Shen, Julian L Ambrus1.   

Abstract

Vasculitides are disease in which injury to blood vessels leads to various degrees and types of organ dysfunction. They are subdivided into different groups dependent on the size of blood vessels involved as well as other particular clinical features. Therapy is dependent upon the size of the blood vessels involved and the nature of the disease. For medium and large vessel vasculitides, glucocorticoids, cyclophosphamide, azathioprine and methotrexate have been the mainstay for induction and maintenance of remission. Because of potential for side effects from standard therapies, various biologic agents have been evaluated in the treatment of ANCA positive vasculitis (AAV), cryoglobulinemic vasculitis, Behcet's disease and Takayasu's Arteritis (TAK). In this article, we present a review on biologic agents used in various vasculitides.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25213365     DOI: 10.2174/138920101506140910151126

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  2 in total

1.  Healthcare utilization and expenditures for United States Medicare beneficiaries with systemic vasculitis.

Authors:  Carolyn T Thorpe; Joshua M Thorpe; Tao Jiang; Dylan Atkinson; Yihuang Kang; Loren J Schleiden; Delesha M Carpenter; Julie Anne G McGregor; Susan L Hogan
Journal:  Semin Arthritis Rheum       Date:  2017-08-10       Impact factor: 5.532

Review 2.  An update of neurological manifestations of vasculitides and connective tissue diseases: a literature review.

Authors:  Anastasia Bougea; Evangelos Anagnostou; Nikolaos Spandideas; Nikolaos Triantafyllou; Evangelia Kararizou
Journal:  Einstein (Sao Paulo)       Date:  2015-08-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.